CNR1 and Parkinson disease: On the one hand, it has been shown that, in PD patients and in animal models of PD, there is a decrease in CB1R expression levels [29,30], as well as an increase in the levels of the endocannabinoids anandamide (AEA) [31,32] and 2-arachidonoyl glycerol (2-AG) [33].